FTSE MIB
34.211,16 -59,96 (-0,17%) Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,99 +0,18 (+0,22%) Bitcoin EUR
59.559,95 -2.544,36 (-4,10%)
Harmony Biosciences Holdings, Inc. (HRMY)
Dopo ore:
| Chiusura precedente | 28,85 |
| Aperto | 28,68 |
| Denaro | 29,14 x 200 |
| Lettera | 29,26 x 200 |
| Min-Max giorno | 28,68 - 29,53 |
| Intervallo di 52 settimane | 18,61 - 39,26 |
| Volume | |
| Media Volume | 370.583 |
| Capitalizzazione | 1,66B |
| Beta (5 anni mensile) | 0,73 |
| Rapporto PE (ttm) | 13,72 |
| EPS (ttm) | 2,13 |
| Prossima data utili | 30 apr 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 41,50 |
GlobeNewswireHarmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023 Exited Second Quarter 2023 With ~5,600 Patients on WAKIX Completed Enrollment in Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study; On-track for Topline Data in Fourth Quarter 2023 Plans to Initiate Prader-Willi Syndrome (PWS) Phase 3 Study in Fourth Quarter 2023 Board of Directors Authorized $1
- GlobeNewswire
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter 2023 Exited First Quarter 2023 With ~5,200 Patients on WAKIX WAKIX Surpassed $1 Billion in Cumulative Net Revenue Since Launch Anticipate Topline Data in Fourth Quarter 2023 in Phase 3 Idiopathic Hypersomnia (“IH”) INTUNE Study Given Continued Strong Momentum Conference Call and Webcast to be Held To
